FMP
Advaxis, Inc.
ADXS
PNK
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
0.03 USD
0 (0%)
Balance Sheet
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Total Cash
16.73M
25.18M
41.61M
25.21M
4.88M
7.27k
4.07k
2.28k
1.27k
712.06
Total Cash %
716.58
9.95k
1.28k
10.08k
37.55k
100
100
100
100
Receivables
469k
469k
681k
234k
-
3.41k
1.91k
1.07k
597.54
334.26
Receivables %
20.09
185.38
21.02
93.6
-
46.94
46.94
46.94
46.94
Inventories
83k
1.34M
-681k
-234k
-
-160.89
-90
-50.35
-28.16
-15.75
Inventories %
3.56
529.25
-21.02
-93.6
-
-2.21
-2.21
-2.21
-2.21
Payable
2.92M
1.08M
2.25M
22k
6.08M
5.5k
3.08k
1.72k
963.34
538.89
Payable %
125.19
427.27
69.6
8.8
46.74k
75.68
75.68
75.68
75.68
Cap Ex
-1.33M
-748k
-460k
-201k
-
-3.66k
-2.05k
-1.14k
-640.49
-358.28
Cap Ex %
-56.98
-295.65
-14.2
-80.4
-
-50.32
-50.32
-50.32
-50.32
